Overview

Short Versus Extended Antibiotic Treatment With a Carbapenem for High-risk Febrile Neutropenia in Hematology Patients With FUO

Status:
Completed

Trial end date:
2019-08-05

Target enrollment:

Participant gender:

Summary

A multicenter open-label non-inferiority randomized clinical trial comparing the safety (non-inferiority) of short antibiotic treatment (72 hours) with an anti-pseudomonal carbapenem with regard to treatment failure in comparison with extended treatment (at least 9 days) of high-risk febrile neutropenia in hematology patients receiving standard antimicrobial prophylaxis.

Phase:

Phase 4

Details

Lead Sponsor:

VU University Medical Center

Collaborators:

FondsNutsOhra
ZonMw: The Netherlands Organisation for Health Research and Development

Treatments:

Anti-Bacterial Agents
Antibiotics, Antitubercular
Cilastatin
Cilastatin, Imipenem Drug Combination
Imipenem
Meropenem
Thienamycins